GLP-1s Have Sex-Specific Brain Effects
GLP-1 drugs like semaglutide and liraglutide have different neurological impacts based on sex, according to a new GLP-1 brain atlas [https://www.miragenews.com/sex-specific-glp-1-brain-atlas-unveils-drug-1634078/]. This discovery could pave the way for more personalized diabetes and obesity management strategies. Will this lead to different dosages for men and women?
The new brain atlas pinpointed GLP-1 expression across 25 brain regions in both sexes of mice. Strikingly, the distribution of GLP-1 in the brain differs significantly between males and females, particularly in areas governing appetite and reward. In females, the ventral tegmental area (VTA), crucial for reward processing, showed GLP-1 expression, while the lateral hypothalamus, linked to motivated behavior, only showed expression in males. Higher GLP-1 densities were found in the female medulla, while males had more in the olfactory bulb. These GLP-1 drugs, including semaglutide and liraglutide, mimic the GLP-1 hormone, naturally released from the gut after eating. They activate GLP-1 receptors in the pancreas and brain, slowing gastric emptying, curbing glucagon release, boosting insulin, and ultimately reducing blood sugar, appetite and food intake. While both sexes benefit, women often experience greater weight loss with GLP-1 receptor agonists. A meta-analysis of trials with nearly 20,000 participants showed women lost 10.88% of their baseline weight, compared to 6.8% for men. This may be due to biological differences like estrogen levels and body composition. However, women also report more adverse effects, such as nausea and vomiting. Research indicates women are more than twice as likely to experience persistent nausea and vomiting when prescribed GLP-1R agonists. This may be linked to higher GLP-1 receptor expression in brain regions processing aversive stimuli in females. These drugs are already reshaping diabetes and obesity treatment. GLP-1 agonists like liraglutide have been approved for obesity treatment. Some GLP-1 agonists are more effective than other weight-loss drugs, but bariatric surgery is still considered the most effective and sustainable way to lose weight. The Mount Sinai atlas should help guide investigations into how GLP-1 acts on neuroinflammation, neuronal degeneration, and memory loss. This is especially important given emerging evidence that GLP-1 analogs may help prevent or treat cognitive decline. The future may bring personalized GLP-1 prescriptions, customized based on individual factors. Researchers are working on tests to predict GLP-1 RA drug tolerability, safety, and efficacy for specific patients.
